Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous infusion versus intermittent administration of meropenem in critically ill patients
2016-002052-24Phase 4Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of meropenem in Systemic Inflammatory Response Syndrome (SIRS), Not applicable and cardiac morbidity (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Composite primary outcome. Started Nov 2020; status: completed.
02
Drugs
meropenem
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)Not applicablecardiac morbidity
Beyond the preview
Go deeper on 2016-002052-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002052-24.